Chimeric antigen receptor T-cell (CAR-T) therapy represents a new frontier in multiple myeloma. It is important to understand critical success factors (CSFs) that may optimize its use in this therapeutic area. We estimated the CAR-T process using time-driven activity-based costing.
View Article and Find Full Text PDFAnn Otolaryngol Chir Cervicofac
January 1985
The choice of a therapeutic strategy for the treatment of mucosal malignant melanomas from upper digestive and respiratory tracts remains difficult. This is due to the very low frequency of such malignancies and to the subsequent scarcity of data on parameters of diagnosis and prognosis. Such informations have been available on cutaneous malignant melanoma as they have been known for a longtime and occur with much higher frequency.
View Article and Find Full Text PDF